134
Participants
Start Date
March 31, 2025
Primary Completion Date
October 31, 2031
Study Completion Date
December 31, 2031
NDI-219216
NDI-219216 is a highly selective small molecule inhibitor of WRN helicase activity.
NOT_YET_RECRUITING
Liverpool Hospital, Liverpool
NOT_YET_RECRUITING
Southern Oncology Clinical Research Unit, Bedford Park
RECRUITING
Cayuga Cancer Center, Ithaca
RECRUITING
Virginia Cancer Specialists, P.C. - Fairfax, Fairfax
RECRUITING
University of Virginia Emily Couric Clinical Cancer Center, Charlottesville
RECRUITING
Prisma Health Cancer Institute - Multidisciplinary Center, Greenville
RECRUITING
University of Louisville James Graham Brown Cancer Center, Louisville
RECRUITING
Taylor Cancer Research Center, Maumee
NOT_YET_RECRUITING
University of Chicago Medicine, Chicago
RECRUITING
USC Norris Comprehensive Cancer Center, Los Angeles
RECRUITING
Brown University Health, Providence
Collaborators (1)
Worldwide Clinical Trials
OTHER
Nimbus Wadjet, Inc.
INDUSTRY